Table 1.
Summary of characteristics for included studies
| Reference | Title | Study type | Country | Funding | Patient engagement |
|---|---|---|---|---|---|
| Ali et al. (2014) [6] | Experiences of patients identifying with chronic Lyme disease in the healthcare system: a qualitative study | Qualitative, in-depth interviews | USA | Government | Yes |
| Berende et al. (2018) [16] | Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease | Economic analysis (alongside clinical trial) | Netherlands | Government | No |
| Boudreau et al. (2018) [27] | Motivations and experiences of Canadians seeking treatment for Lyme disease outside of the conventional Canadian health-care system | Survey; semi-structured; qualitative | Canada | None | Yes |
| Drew & Hewitt (2006) [30] | A qualitative approach to understanding patients’ diagnosis of Lyme disease | Qualitative, in-depth interviews | USA | Private non-profit | Yes |
| Eckman et al. (1997) [31] | Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis | Economic analysis (model) | USA | Government | No |
| Fix et al. (1998) [32] | Tick bites and Lyme disease in an endemic setting | Observational (prospective cohort) | USA | Government | No |
| Gasmi et al. (2017) [33] | Practices of Lyme disease diagnosis and treatment by general practitioners in Quebec, 2008–2015 | Observational (retrospective cohort) | Canada | Government | No |
| Henningsson et al. (2010) [34] | Neuroborreliosis - an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden | Observational (retrospective cohort) | Sweden | Private non-profit | No |
| Hsia et al. (2002) [35] | Cost-effectiveness analysis of the Lyme disease vaccine | Economic analysis (model) | USA | Private non-profit | No |
| Johnson et al. (2011) [36] | Healthcare access and burden of care for patients with Lyme disease: a large United States survey | Survey; quantitative | USA | None | Yes |
| Johnson et al. (2014) [17] | Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey | Survey; quantitative | USA | None | Yes |
| Joss et al. (2003) [18] | Lyme disease - what is the cost for Scotland? | Observational (prospective cohort) | Scotland | Government | No |
| Lantos et al. (2013) [19] | Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study | Economic analysis (model) | USA | None | No |
| Lightfoot Jr et al. (1993) [20] | Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: a cost-effectiveness analysis | Economic analysis (model) | USA | None | No |
| Lohr et al. (2015) [21] | Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysis | Observational (cost-of-illness) | Germany | Government | No |
| Maes et al. (1998) [29] | A cost-of-illness study of Lyme disease in the United States | Economic analysis (cost-of-illness) | USA | Private for-profit | No |
| Magid et al. (1992) [22] | Prevention of Lyme disease after tick bites - a cost-effectiveness analysis | Economic analysis (model) | USA | Government | No |
| Meltzer et al. (1999) [23] | The cost effectiveness of vaccinating against Lyme disease | Economic analysis (model) | USA | Government | No |
| Nichol et al. (1998) [24] | Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis | Economic analysis (model) | USA | None | No |
| Shadick et al. (2001) [25] | The cost-effectiveness of vaccination against Lyme disease | Economic analysis (model) | USA | Government | No |
| van den Wijngaard et al. (2017) [26] | The cost of Lyme borreliosis | Observational (cost of illness) | Netherlands | Government | Yes |
| Zhang et al. (2006) [28] | Economic impact of Lyme disease | Observational (case-control) | USA | Government | Yes |